Business
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenues representing the majority of sales and accelerating year over year Strategic firepower: Year-end cash, cash equivalents...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma.","length":172,"tagName":"p"},{"type":"text","content":"Financial Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenues representing the majority of sales and accelerating year over year","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic firepower: Year-end cash, cash equivalents and short-term investments above €128 million with zero debt, significantly above guidance, enabling disciplined M&A, licensing, and platform expansion","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating inflection: EBITDA at the upper end of guidance (€5.5 to €7.5 million), confirming operating leverage as scale builds","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":511,"olType":false},{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - January 12, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reports strong preliminary unaudited 2025 revenue and year end cash, reflecting continued revenue growth and a robust cash position. Cosmo will publish its 2025 audited consolidated financial statements as well as the Annual and ESG Reports 2025 on March 9, 2026.","length":378,"tagName":"p"},{"type":"text","content":"Preliminary Unaudited Revenue and Cash","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue: €104 million, of which €88 million is from recurring revenues and €16 million is from project-based revenues. Recurring revenues grew €12 million vs. 2024, representing 15% year over year growth, driven mainly by GI Genius™ and Winlevi®.","length":246,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash Position: Year-end cash, equivalents, and short-term investments above €128 million, reflecting a very strong operational performance and focus.","length":149,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":395,"olType":false},{"type":"text","content":"Business and pipeline update...